Drug interactions
Irinotecan liposomal + Lorlatinib
Severity: Moderate
Irinotecan liposomal and Lorlatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a moderate CYP3A4 inducer and may lower exposure to irinotecan and its active metabolite SN-38. Reduced exposure could weaken antitumor activity.
What this interaction means in plain words
Irinotecan liposomal and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Lorlatinib induces CYP3A4, which increases the metabolism of irinotecan to inactive oxidized metabolites.
What to do
Monitor tumor response and tolerability closely if both are given. Consider an alternative to lorlatinib or review the regimen if efficacy appears reduced.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Irinotecan liposomal and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Irinotecan liposomal with Lorlatinib?
MediHelp rates the interaction as moderate. Irinotecan liposomal and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib is a moderate CYP3A4 inducer and may lower exposure to irinotecan and its active metabolite SN-38. Reduced exposure could weaken antitumor activity.
How serious is the interaction between Irinotecan liposomal and Lorlatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor tumor response and tolerability closely if both are given. Consider an alternative to lorlatinib or review the regimen if efficacy appears reduced.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
